These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28182563)

  • 1. A high-throughput small molecule screen identifies synergism between DNA methylation and Aurora kinase pathways for X reactivation.
    Lessing D; Dial TO; Wei C; Payer B; Carrette LL; Kesner B; Szanto A; Jadhav A; Maloney DJ; Simeonov A; Theriault J; Hasaka T; Bedalov A; Bartolomei MS; Lee JT
    Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14366-14371. PubMed ID: 28182563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Throughput Screening of a Luciferase Reporter of Gene Silencing on the Inactive X Chromosome.
    Keegan A; Plath K; Damoiseaux R
    Methods Mol Biol; 2018; 1755():75-87. PubMed ID: 29671264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aurora kinases as targets in drug-resistant neuroblastoma cells.
    Michaelis M; Selt F; Rothweiler F; Löschmann N; Nüsse B; Dirks WG; Zehner R; Cinatl J
    PLoS One; 2014; 9(9):e108758. PubMed ID: 25268132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reestablishment of the inactive X chromosome to the ground state through cell fusion-induced reprogramming.
    Choi HW; Kim JS; Jang HJ; Choi S; Kim JH; Schöler HR; Do JT
    Cell Mol Life Sci; 2012 Dec; 69(23):4067-77. PubMed ID: 26250157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
    Noronha S; Alt LAC; Scimeca TE; Zarou O; Obrzut J; Zanotti B; Hayward EA; Pillai A; Mathur S; Rojas J; Salamah R; Chandar N; Fay MJ
    In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):71-84. PubMed ID: 29197031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high-throughput screen of inactive X chromosome reactivation identifies the enhancement of DNA demethylation by 5-aza-2'-dC upon inhibition of ribonucleotide reductase.
    Minkovsky A; Sahakyan A; Bonora G; Damoiseaux R; Dimitrova E; Rubbi L; Pellegrini M; Radu CG; Plath K
    Epigenetics Chromatin; 2015; 8():42. PubMed ID: 26468331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
    Zhou N; Singh K; Mir MC; Parker Y; Lindner D; Dreicer R; Ecsedy JA; Zhang Z; Teh BT; Almasan A; Hansel DE
    Clin Cancer Res; 2013 Apr; 19(7):1717-28. PubMed ID: 23403633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.
    Fiskus W; Hembruff SL; Rao R; Sharma P; Balusu R; Venkannagari S; Smith JE; Peth K; Peiper SC; Bhalla KN
    Breast Cancer Res Treat; 2012 Sep; 135(2):433-44. PubMed ID: 22825030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput kinase inhibitor screening reveals roles for Aurora and Nuak kinases in neurite initiation and dendritic branching.
    Blazejewski SM; Bennison SA; Liu X; Toyo-Oka K
    Sci Rep; 2021 Apr; 11(1):8156. PubMed ID: 33854138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.
    Tuccilli C; Baldini E; Prinzi N; Morrone S; Sorrenti S; Filippini A; Catania A; Alessandrini S; Rendina R; Coccaro C; D'Armiento M; Ulisse S
    Endocrine; 2016 May; 52(2):287-95. PubMed ID: 26215279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
    Mahadevan D; Stejskal A; Cooke LS; Manziello A; Morales C; Persky DO; Fisher RI; Miller TP; Qi W
    Clin Cancer Res; 2012 Apr; 18(8):2210-9. PubMed ID: 22374334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.
    Wang S; Hwang EE; Guha R; O'Neill AF; Melong N; Veinotte CJ; Conway Saur A; Wuerthele K; Shen M; McKnight C; Alexe G; Lemieux ME; Wang A; Hughes E; Xu X; Boxer MB; Hall MD; Kung A; Berman JN; Davis MI; Stegmaier K; Crompton BD
    Clin Cancer Res; 2019 Jul; 25(14):4552-4566. PubMed ID: 30979745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lineage-specific function of the noncoding Tsix RNA for Xist repression and Xi reactivation in mice.
    Ohhata T; Senner CE; Hemberger M; Wutz A
    Genes Dev; 2011 Aug; 25(16):1702-15. PubMed ID: 21852535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders.
    Carrette LLG; Wang CY; Wei C; Press W; Ma W; Kelleher RJ; Lee JT
    Proc Natl Acad Sci U S A; 2018 Jan; 115(4):E668-E675. PubMed ID: 29282321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.
    Kai K; Kondo K; Wang X; Xie X; Pitner MK; Reyes ME; Torres-Adorno AM; Masuda H; Hortobagyi GN; Bartholomeusz C; Saya H; Tripathy D; Sen S; Ueno NT
    Mol Cancer Ther; 2015 Dec; 14(12):2687-99. PubMed ID: 26443806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymer Nanovesicle-Mediated Delivery of MLN8237 Preferentially Inhibits Aurora Kinase A To Target RalA and Anchorage-Independent Growth in Breast Cancer Cells.
    Inchanalkar S; Deshpande NU; Kasherwal V; Jayakannan M; Balasubramanian N
    Mol Pharm; 2018 Aug; 15(8):3046-3059. PubMed ID: 29863884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
    Qi W; Cooke LS; Liu X; Rimsza L; Roe DJ; Manziolli A; Persky DO; Miller TP; Mahadevan D
    Biochem Pharmacol; 2011 Apr; 81(7):881-90. PubMed ID: 21291867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
    Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
    Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
    Muscal JA; Scorsone KA; Zhang L; Ecsedy JA; Berg SL
    Invest New Drugs; 2013 Feb; 31(1):39-45. PubMed ID: 22669335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.